PTH compounds with low peak-to-trough ratios

A method of treating a human patient having hypoparathyroidism comprising subcutaneously administering to the subject a PTH compound, wherein the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one administration interval at a steady state,

• wherein the PTH compound is a water-soluble controlled-release PTH compound of formula (Ia) or a pharmaceutically acceptable salt thereof:
• wherein
• -D is a PTH moiety, which has the sequence of SEQ ID NO:
• 51;
• -L2-L1- has the formula:
• wherein the unmarked dashed line indicates the attachment to a nitrogen of -D by an amide bond;
• and the dashed line marked with an asterisk indicates attachment to —Z;
• x is 1;
• —Z comprises a moiety of formula (b):
• wherein the dashed line indicates attachment to -L2 and m and p are independently of each other an integer ranging from 150-1000;
• and
• the PTH moiety is released with a release half-life of at least 12 hours.